Ensign Peak Advisors’s Korro Bio KRRO Stock Holding History

Ensign Peak Advisors’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-672	Closed	-$1.19M	–	1861
2020 Q4	$1.19M	Buy	672 +386	+135%	+$510K	﹤0.01%	1327
2020 Q3	$275K	Buy	+286	New	+$307K	﹤0.01%	1638

Other funds holding KRRO

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ensign Peak Advisors's KRRO Position: Q1 2021 in Review

Ensign Peak Advisors sold out of Korro Bio (KRRO) in Q1 2021, closing a stake of 672 shares — an estimated $1.19M sold.

Ensign Peak Advisors first reported a position in KRRO in Q3 2020 and held it in 2 quarters. The position peaked at $1.19M in Q4 2020. 115 funds tracked by Wall St. Rank hold KRRO as of Q1 2021.

Ensign Peak Advisors reported no remaining Korro Bio position as of Q1 2021 after selling out during the quarter.
Ensign Peak Advisors sold 672 Korro Bio shares in Q1 2021, an estimated $1.19M.
Ensign Peak Advisors first reported a position in Korro Bio in Q3 2020 and held it in 2 quarters.
Ensign Peak Advisors's Korro Bio position peaked at $1.19M in Q4 2020.
115 funds tracked by Wall St. Rank held Korro Bio as of Q1 2021.

Based on Ensign Peak Advisors's 13F filing for Q1 2021, filed 12 May 2021.